JP2006506101A - インフルエンザウイルス非構造タンパク質１の阻害剤を設計する方法 - Google Patents

インフルエンザウイルス非構造タンパク質１の阻害剤を設計する方法 Download PDF

Info

Publication number
JP2006506101A
JP2006506101A JP2005507162A JP2005507162A JP2006506101A JP 2006506101 A JP2006506101 A JP 2006506101A JP 2005507162 A JP2005507162 A JP 2005507162A JP 2005507162 A JP2005507162 A JP 2005507162A JP 2006506101 A JP2006506101 A JP 2006506101A
Authority
JP
Japan
Prior art keywords
dsrna
protein
ns1a
influenza virus
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005507162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506101A5 (enExample
Inventor
モンテリオーネ，ガエターノ・ティー
クルーグ，ロバート・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of JP2006506101A publication Critical patent/JP2006506101A/ja
Publication of JP2006506101A5 publication Critical patent/JP2006506101A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2005507162A 2002-11-13 2003-11-13 インフルエンザウイルス非構造タンパク質１の阻害剤を設計する方法 Pending JP2006506101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42566102P 2002-11-13 2002-11-13
US47745303P 2003-06-10 2003-06-10
PCT/US2003/036292 WO2004043404A2 (en) 2002-11-13 2003-11-13 Process for designing inhibitors of influenza virus non-structural protein 1

Publications (2)

Publication Number Publication Date
JP2006506101A true JP2006506101A (ja) 2006-02-23
JP2006506101A5 JP2006506101A5 (enExample) 2007-02-01

Family

ID=32314599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005507162A Pending JP2006506101A (ja) 2002-11-13 2003-11-13 インフルエンザウイルス非構造タンパク質１の阻害剤を設計する方法

Country Status (5)

Country Link
US (2) US20080234175A1 (enExample)
JP (1) JP2006506101A (enExample)
AU (1) AU2003290842A1 (enExample)
CA (1) CA2505949A1 (enExample)
WO (1) WO2004043404A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101471245B1 (ko) * 2012-05-31 2014-12-10 충북대학교 산학협력단 Ａ형 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
BR122015032743B1 (pt) 2004-06-01 2018-04-03 Mount Sinai School Of Medicine Of New York University Vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, seus usos e métodos para produzir uma vacina
EP1855713B1 (en) * 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
US20090221808A1 (en) * 2005-11-07 2009-09-03 Fazio Michael J Process for the Preparation of Nucleic Acid Duplexes
WO2007061969A2 (en) 2005-11-18 2007-05-31 Rutgers, The State University Vaccines against influenza a and influenza b
US7709190B2 (en) 2005-12-02 2010-05-04 Board Of Regents, The University Of Texas System Influenza A virus vaccines and inhibitors
US7601490B2 (en) 2005-12-02 2009-10-13 Board Of Regents, The University Of Texas System Development of influenza A antivirals
CN102002489B (zh) * 2009-09-02 2013-06-12 中国科学院微生物研究所 抑制H1N1型流感病毒增殖的microRNA及其应用
WO2011147199A1 (en) * 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
EP3261664A1 (en) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
EP4412592A4 (en) * 2021-10-06 2025-11-19 Seqirus Inc LIPID NANOPARTICLE COMPRISING A NUCLEIC ACID-BINDING PROTEIN

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750394A (en) * 1994-05-20 1998-05-12 The Mount Sinai Medical Center Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication
US5843724A (en) * 1995-04-27 1998-12-01 Rutgers University Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
EP1015889A1 (en) * 1997-09-12 2000-07-05 Genelabs Technologies, Inc. dsRNA/dsRNA-BINDING PROTEIN METHODS AND COMPOSITIONS

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6009051271, Ｎａｔ． Ｓｔｒｕｃｔ． Ｂｉｏｌ．, 1997, ｖｏｌ．４， ｎｏ．１１, ｐ．８９６−８９９ *
JPN6009051274, Ｎａｔ． Ｓｔｒｕｃｔ． Ｂｉｏｌ．, 1997, ｖｏｌ．４， ｎｏ．１１, ｐ．８９１−８９５ *
JPN6009051276, Ｖｉｒｏｌｏｇｙ, 1996, ｖｏｌ．２２３， ｎｏ．１, ｐ．４１−５０ *
JPN6009051278, Ｖｉｒｏｌｏｇｙ, 1995, ｖｏｌ．２１４， ｎｏ．１, ｐ．２２２−２２８ *
JPN6009051280, ＲＮＡ, 1995, ｖｏｌ．１， ｎｏ．５, ｐ．９４８−９５６ *
JPN6009051281, Ｊ． Ｖｉｒｏｌ．, 1994, ｖｏｌ．６８， ｎｏ．４, ｐ．２４３３−２４４１ *
JPN6009051283, Ｊ． Ｇｅｎ． Ｖｉｒｏｌ．, 1992, ｖｏｌ．７３， ｎｏ．１２, ｐ．３３２５−３３２９ *
JPN6009051285, ＲＮＡ, 1999, ｖｏｌ．５， ｎｏ．２, ｐ．１９５−２０５ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101471245B1 (ko) * 2012-05-31 2014-12-10 충북대학교 산학협력단 Ａ형 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
WO2004043404A2 (en) 2004-05-27
WO2004043404A3 (en) 2004-09-23
US20080234175A1 (en) 2008-09-25
AU2003290842A8 (en) 2004-06-03
AU2003290842A1 (en) 2004-06-03
US20100081126A1 (en) 2010-04-01
CA2505949A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
US20100081126A1 (en) Process for designing inhibitors of influenza virus structural protein-1
Zhao et al. Influenza virus infection causes global RNAPII termination defects
Serrano et al. Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus
US9029526B2 (en) Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection
Cox et al. Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase
Wang et al. Nuclear factor 90 negatively regulates influenza virus replication by interacting with viral nucleoprotein
Bruns et al. Structural characterization and oligomerization of PB1-F2, a proapoptotic influenza A virus protein
Zhirnov et al. Histones as a target for influenza virus matrix protein M1
Kakisaka et al. A novel antiviral target structure involved in the RNA binding, dimerization, and nuclear export functions of the influenza A virus nucleoprotein
Li et al. SRSF5‐mediated alternative splicing of M gene is essential for influenza a virus replication: a host‐directed target against influenza virus
Yu et al. The molecular evolutionary characteristics of new isolated H9N2 AIV from East China and the function of vimentin on virus replication in MDCK cells
Lecoq et al. Solid-state [13C–15N] NMR resonance assignment of hepatitis B virus core protein
Wang et al. Guanidine modifications enhance the anti‐herpes simplex virus activity of (E, E)‐4, 6‐bis (styryl)‐pyrimidine derivatives in vitro and in vivo
Mizuta et al. Lead optimization of influenza virus rna polymerase inhibitors targeting pa–pb1 interaction
Ferrié et al. The AP-1 adaptor complex is essential for intracellular trafficking of the ORF2 capsid protein and assembly of Hepatitis E virus
Diefenbacher et al. Interactions between influenza A virus nucleoprotein and gene segment untranslated regions facilitate selective modulation of viral gene expression
Li et al. Characterization of RNA G-quadruplexes in porcine epidemic diarrhea virus genome and the antiviral activity of G-quadruplex ligands
Lan et al. Screening and identification of Lassa virus endonuclease-targeting inhibitors from a fragment-based drug discovery library
Borin et al. Murine norovirus protein NS1/2 aspartate to glutamate mutation, sufficient for persistence, reorients side chain of surface exposed tryptophan within a novel structured domain
Yang et al. SARS‐CoV‐2 NSP12 utilizes various host splicing factors for replication and splicing regulation
Johnson et al. NMR structure of the SARS-CoV nonstructural protein 7 in solution at pH 6.5
Woltz et al. The NS1 protein of influenza B virus binds 5’-triphosphorylated dsRNA to suppress RIG-I activation and the host antiviral response
WO2022023734A1 (en) Coronaviral packaging signals
Jung et al. The artificial amino acid change in the sialic acid-binding domain of the hemagglutinin neuraminidase of newcastle disease virus increases its specificity to HCT 116 colorectal cancer cells and tumor suppression effect
JP6566368B2 (ja) Ｂ型肝炎ウイルス分泌阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100330